Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Affiliation: CAR Mechanics Group, King's College London, King's Health Partners Integrated Cancer Centre, Department of Research Oncology, Guy's Hospital Campus, Great Maze Pond, London SE1 9RT, UK.
The CD19 molecule is ubiquitously expressed throughout all stages of B-cell differentiation, but is not found
on haemopoietic stem cells. Since most B-cell leukaemias and lymphomas retain CD19 expression, it represents an excellent
target for immunotherapy of these malignant disorders. Over the past 10 years, compelling pre-clinical evidence has
accrued to indicate that expression of a CD19-targeted chimeric antigen receptor (CAR) in peripheral blood T-cells exerts
therapeutic efficacy in diverse models of B-cell malignancy. Building on this, clinical studies are ongoing in several centres
in which autologous CD19-specific CAR T-cells are undergoing evaluation in patients with acute and chronic B-cell
leukaemia and refractory lymphoma. Early data have generated considerable excitement, providing grounds to speculate
that CAR-based immunotherapy will radically alter existing management paradigms in B-cell malignancy. The focus of
this mini-review is to evaluate these emerging clinical data and to speculate on clinical prospects for this new therapeutic
Keywords: Adoptive immunotherapy, CD19, chimeric antigen receptor, gene therapy, leukaemia, lymphoma.
Rights & PermissionsPrintExport